Jared Kaltwasser

Various therapies have different impacts on brain volume loss in patients with relapsing multiple sclerosis (MS), a new study has found.

A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.

Investigators said the unique features of chimeric antigen receptor (CAR) T-cell therapy may warrant novel approaches to cost-effectiveness analysis.

Investigators say thrombospondin-4 levels were reduced in patients with symptoms of spinal muscular atrophy (SMA), but levels of the protein increased after therapy.

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients with acute myeloid leukemia (AML) with internal tandem duplication in the fms-like tyrosine kinase 3 (FLT3) gene.

The study is among the first to look at the potential impacts of clonal dynamics on patients with lower-risk myelodysplastic syndromes (MDS).

A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.

Insulin resistance plays a role in many diseases. The new research provides insights into why insulin resistance appears to be associated with neurodegenerative disorders.

Most patients diagnosed with chronic-phase chronic myeloid leukemia (CP-CML) who achieved a deep molecular response on tyrosine kinase inhibitor (TKI) therapy were able to avoid relapse despite discontinuing therapy.

However, an analysis suggested that androgenetic alopecia is not caused by hypothyroidism.

A study suggests most patients with myasthenia gravis (MG) can take statins without experiencing symptom worsening.

Health plans would see savings faster if they switched to etranacogene dezaparvovec sooner, the investigators found.

New research shows how repetitive nerve stimulation and single fiber electromyography can help diagnose disorders such as myasthenia gravis.

Though magnesium has long been seen as a potential sleep aid, the authors say the new form of magnesium salt may provide a clearer benefit.

Researchers say machine learning advances make it possible to use more sophisticated body composition analyses to assess risk of mortality from idiopathic pulmonary fibrosis (IPF).

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood.

The tentative approval cannot take effect because a competing product was granted market exclusivity.

Early data suggest chimeric antigen receptor (CAR) T-cell therapy can achieve meaningful long-term results.

A survey of patients with myasthenia gravis in 5 European countries suggests patients wait on average about a year after symptom onset before they are given an accurate diagnosis.

Improvements in multiplex immunofluorescence and spatial analysis have enabled a better understanding of the ways classical Hodgkin lymphoma evades the immune system.

The authors said their findings also suggest AXL inhibition might be an important therapeutic strategy.

Though circulating high mobility group box-1 levels appear to be a biomarker for pulmonary arterial hypertension (PAH) in adults with congenital heart disease, the same is not true in pediatric patients.

A mathematical model using pharmacodynamic parameters, including duration of hyperlymphocytosis, may help clinicians better predict patient responses to ibrutinib administered for chronic lymphocytic leukemia (CLL).

A case report suggests vigilance is required even when cancers like acute lymphoblastic leukemia appear to go into remission without explanation.

Experts argue for new mechanisms to fund research in oft-ignored rare diseases.

Better reporting is needed to create better guidelines for tracking infection risk in patients with relapsed or refractory non-Hodgkin lymphoma or multiple myeloma, investigators concluded.

The analysis represents an effort to use bioinformatics to find potential new therapeutic targets for myasthenia gravis (MG).

Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.

Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs).

Investigators wanted to know how well the NFlymSI-18 assessment was able to assess patient-reported outcomes in people with indolent B-cell non-Hodgkin lymphoma (NHL).